Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2754578 | 1.00 | TSHR (0.31) | TSHRCYP2C9 | |
| SCHEMBL14296166 | 0.91 | TSHR (0.31) | TSHRCYP2C9 | |
| SCHEMBL15811680 | 0.86 | — | — | |
| SCHEMBL16455237 | 0.85 | CYP2C9 (0.32) | TSHRCYP2C9 | |
| SCHEMBL16645098 | 0.85 | — | — | |
| SCHEMBL13246463 | 0.82 | — | — | |
| SCHEMBL16645134 | 0.81 | CYP2C9 (0.30) | TSHRCYP2C9 | |
| SCHEMBL14884262 | 0.81 | — | — | |
| SCHEMBL16143202 | 0.81 | — | — | |
| SCHEMBL10067038 | 0.81 | CYP2C9 (0.34) | TSHRCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9943609-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170348424-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| US-9770519-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-20160220696-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2016-08-04 | — | — | US | disclosed |
| US-20160067353-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2016-03-10 | — | — | US | disclosed |
| US-9254339-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2016-02-09 | — | — | US | disclosed |
| US-20160022829-A1 | TUBULYSIN COMPOUNDS AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20150314008-A1 | AURISTATIN COMPOUNDS AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2015-11-05 | — | — | US | disclosed |
| US-9144615-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20150064130-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2015-03-05 | — | — | US | disclosed |
| US-8546419-B2 | Dual phase drug release system | THE GENERAL HOSPITAL CORPORATION (US) | 2013-10-01 | — | — | US | disclosed |
| US-20130101546-A1 | Protein-Polymer-Drug Conjugates | MERSANA THERAPEUTICS, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-20120321583-A1 | Protein-Polymer-Drug Conjugates | MERSANA THERAPEUTICS, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120289535-A1 | DUAL PHASE DRUG RELEASE SYSTEM | THE GENERAL HOSPITAL CORPORATION (US) | 2012-11-15 | — | — | US | disclosed |
| US-8247427-B2 | Dual phase drug release system | THE GENERAL HOSPITAL CORPORATION (US) | 2012-08-21 | — | — | US | disclosed |
| US-8101164-B2 | Dual phase drug release system | THE GENERAL HOSPITAL CORPORATION (US) | 2012-01-24 | — | — | US | disclosed |
| US-20120004255-A1 | DUAL PHASE DRUG RELEASE SYSTEM | THE GENERAL HOSPITAL CORPORATION (US) | 2012-01-05 | — | — | US | disclosed |
| US-20110059010-A1 | DUAL PHASE DRUG RELEASE SYSTEM | THE GENERAL HOSPITAL CORPORATION (US) | 2011-03-10 | — | — | US | disclosed |
| US-7790150-B2 | Dual phase drug release system | THE GENERAL HOSPITAL CORPORATION (US) | 2010-09-07 | — | — | US | disclosed |
| US-20070190018-A1 | Dual phase drug release system | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059010-A1 | DUAL PHASE DRUG RELEASE SYSTEM | SUCNR1, SUCLA2, SUMO2 | TSHR 1701/4885CYP2C9 1587/4885 |
| US-20170348424-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, CLTB, BRAP | TSHR 3548/4885CYP2C9 4292/4885 |
| US-20160022829-A1 | TUBULYSIN COMPOUNDS AND CONJUGATES THEREOF | LGMN, TLL1, TEK | TSHR 2441/4885CYP2C9 4854/4885 |
| US-20160067353-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, CLTB, BRAP | TSHR 3548/4885CYP2C9 4292/4885 |
| US-20120289535-A1 | DUAL PHASE DRUG RELEASE SYSTEM | SUCNR1, SUCLA2, SUMO2 | TSHR 1798/4885CYP2C9 1571/4885 |
| US-20120321583-A1 | Protein-Polymer-Drug Conjugates | PBRM1, CLTB, BRAP | TSHR 3548/4885CYP2C9 4292/4885 |
| US-20070190018-A1 | Dual phase drug release system | SUCNR1, SUCLA2, SUCLG2 | TSHR 1864/4885CYP2C9 1208/4885 |
| US-20160220696-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, PEBP1, STAMBP | TSHR 3669/4885CYP2C9 4593/4885 |
| US-20120004255-A1 | DUAL PHASE DRUG RELEASE SYSTEM | SUCNR1, SUCLA2, SUMO2 | TSHR 1798/4885CYP2C9 1571/4885 |
| US-20150064130-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, PEBP1, STAMBP | TSHR 3669/4885CYP2C9 4593/4885 |
| US-20150314008-A1 | AURISTATIN COMPOUNDS AND CONJUGATES THEREOF | PBRM1, BRWD1, BRDT | TSHR 2924/4885CYP2C9 4816/4885 |
| US-20130101546-A1 | Protein-Polymer-Drug Conjugates | PBRM1, CLTB, BRAP | TSHR 3572/4885CYP2C9 4086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.